Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase.
With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc.
In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.
Company Details
- Employees
- 25
- Founded
- -
- Address
- 174-10 Jagok-Ro, Gangnam-Gu, Suite #218 / #608,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- shaperon.com
- Keywords
- nanobody, DAMPs, oncology, inflammation, TGR5, Atopy, sepsis, Alzheimer, Ulcerative colitis, stomach cancer, colon cancer, immune, 인플라마좀, 아토피 피부염, 항염증제, 나노바디, 알츠하이머, 코로나19치료제, 면역학, 항체치료제, 패혈증, 염증복합체 억제제, Immunology, 면역항암제, 항암.
- HQ
- Seoul
Shaperon Questions
Shaperon's website is shaperon.com
Shaperon's LinkedIn profile is https://kr.linkedin.com/company/shaperon
Shaperon has
25 employees.
View email and phone details for 25
employees at Shaperon.
Shaperon's industry is
Biotechnology Research
Shaperon's categories are Biotechnology Research
Shaperon's founding year is 2008
